ClinicalTrials.gg
Active, not recruitingNCT03696030Updated Aug 12, 2026

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

A Phase 1 interventional study of Chimeric Antigen Receptor T-Cell Therapy in Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain and Metastatic Malignant Neoplasm in the Leptomeninges, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Primary conditionBreast NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. The study's listed conditions name Breast Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.

Enrollment
47th of 76
24 · median 36
Started
2018
with 2 others
Phase 1
14 of 89
2 open now
Primary completion
2027-01
later than 17 of 38 live
Registered
64th of 89
by date

Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 47th largest by enrollment of the 76 interventional ones that give a count, is one of 3 that started in 2018, is one of 14 in phase 1, reaches primary completion later than 17 of the 38 other live ones, and was the 64th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Breast Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent). HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the safety and recommended phase 2 dosing (RP2D) of intraventricularly administered memory-enriched autologous HER2(EQ)BBzeta/CD19t+ T cells (HER2-chimeric antigen receptor [CAR] T cells) - either HER2(EQ)BBzeta/CD19t+ TCM in Arm 1, or HER2(EQ)BBzeta/CD19t+ TN/MEM in Arm 2 - in participants with brain and/or leptomeningeal metastases from HER2 positive cancers.

SECONDARY OBJECTIVES:

I. Assess cerebrospinal fluid (CSF) and peripheral blood for HER2-CAR T cell persistence and endogenous immune system activation.

II. Describe changes in cytokine levels in the CSF and peripheral blood. III. Describe changes in circulating tumor cells in the CSF.

IV. In study participants who complete at least the first three cycles of HER2-CAR T cell infusions:

IVa. Describe the CNS clinical benefit defined as disease response rate based on Response Assessment in Neuro-Oncology Criteria (RANO) criteria (stable disease [SD], partial response [PR], or complete response [CR] in the brain).

IVb. Describe the systemic clinical benefit based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

IVc. Estimate the median central nervous system (CNS) progression-free and overall survival rates (mPFS and mOS), (newly diagnosed versus recurrent metastases).

V. In study participants who undergo tumor resection or biopsy during or after study treatment or upon autopsy, evaluate the tumor micro-environment for:

Va. HER2-CAR T cell persistence. Vb. Immune cell subsets. Vc. Cytokine levels. Vd. HER2 antigen expression levels. VI. Use biomathematical modeling of tumor growth to evaluate benefit of treatment.

OUTLINE: This is a dose-escalation study.

Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.

After completion of study treatment, participants are followed up at 4 weeks, 3, 6, 8, 10, and 12 months, and then for up to 15 years.

03

Conditions studied

  • Malignant Neoplasm
  • Metastatic Malignant Neoplasm in the Brain
  • Metastatic Malignant Neoplasm in the Leptomeninges
  • Breast Cancer
  • HER2-positive Breast Cancer

Browse trials for

04

In context

Breast Neoplasms Reclassified

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 24 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCREENING: Participant has treated brain and/or that has not recurred OR

    • Such participants are eligible to enroll in the study and undergo leukapheresis, but they cannot start treatment with -CAR T cells until there is evidence of tumor progression/recurrence
  • SCREENING: Participant has recurrent after radiation therapy OR
  • SCREENING: Participant has recurrent leptomeningeal metastases after intrathecal chemotherapy OR
  • SCREENING: Participant has untreated brain or leptomeningeal metastases and refuses to undergo radiation and/or intrathecal chemotherapy

    • Note: Participants with leptomeningeal metastasis (diagnosed by positive CSF cytology or characteristic findings on brain or spine magnetic resonance imaging [MRI]) may have concomitant brain metastases, but having both is not required
  • SCREENING: Participant must have a performance status (KPS) >= 70
  • SCREENING: Participant must have a of >= 8 weeks
  • SCREENING: The effects of HER2-CAR T cells on a developing fetus are unknown. For this reason, women of must have negative serum pregnancy test and agree to use a reliable form of prior to study entry and for at least two months following duration of study participation. Male research participants must agree to use a reliable form of birth control and not donate sperm during the study and for at least six months afterwards
  • SCREENING: Participant has a confirmed cancer which is HER2+, defined as 3+ by immunohistochemistry (IHC) or gene amplification by fluorescence in situ hybridization (FISH)
  • SCREENING: Participant must have the ability to understand and the willingness to sign a written
  • ELIGIBILITY TO PROCEED WITH LEUKAPHERESIS: At least 2 weeks must have elapsed since the participant received his/her last dose of prior targeted agents, chemotherapy or radiation; at the PI's discretion, exception can be made for agents that are delivered locally into the CSF
  • ELIGIBILITY TO PROCEED WITH LEUKAPHERESIS: Research participant must not require more than 6 mg/day of dexamethasone (or the equivalent dose of another ) on the day of leukapheresis
  • ELIGIBILITY TO PROCEED WITH LEUKAPHERESIS: Participant must be willing to undergo placement of a catheter for central venous access if s/he does not have adequate peripheral venous access for collection of T cells
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: Creatinine \< 1.6 mg/dL
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: White blood cell (WBC) > 2,000/uL (or [ANC] > 1,000)
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: >= 100,000/uL
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: (INR) must be \< 1.3
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: \< 1.5 mg/dL
  • ELIGIBILITY TO PROCEED WITH RICKHAM RESERVOIR PLACEMENT: (ALT) and aspartate aminotransferase (AST) \< 2.5 X
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Participant must be taking =\< 6 mg/ day of dexamethasone (or the equivalent dose of another corticosteroid) during CAR T cell therapy
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Participants agrees to stop treatment with chemotherapy or endocrine therapy during the first 3 cycles of the HER2-CAR T cell study
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Participant does not have evidence of active infection and does not have a fever exceeding 38.5 degrees C; there is an absence of positive blood culture for bacteria, fungus, or virus within 48-hours prior to HER2-CAR T cell infusion and/or there aren't any indications of meningitis
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: WBC > 2,000/uL (or ANC > 1,000)
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Platelets > 100,000/uL. However, if platelet level is between 75,000-99,000/uL then HER2-CAR T-cell administration may proceed after platelet transfusion is given, and the post transfusion platelet count is >= 100,000/uL
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Serum creatinine \< 1.8 mg/dL
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Serum total bilirubin or transaminases does not exceed 2 X upper limits of normal
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Research participant does not require supplemental oxygen to keep saturation greater than 95% and/or does not have presence of any radiographic abnormalities on chest x-ray that are positive
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Research participant does NOT have any known history of congestive heart failure (CHF) or cardiac symptoms consistent with (NYHA) classification III-IV within 6 months prior to day 1 of protocol treatment, cardiomyopathy, myocarditis, myocardial infarction (MI), exposure to cardiotoxic medications or with clinical history suggestive of the above must have an (EKG) and echocardiogram (ECHO) performed within 42 days prior to registration and as clinically indicated while on treatment

    • If the research participant has new symptoms of congestive heart failure (CHF), cardiomyopathy, myocarditis, MI, or exposure to cardiotoxic medications, they already had a cardiac consultation, creatinine phosphokinase (CPK), and troponin testing at pre study deeming them fit for study participation
  • ELIGIBILITY FOR ENROLLMENT AND TO PROCEED WITH INTRAVENTRICULAR ADMINISTRATION OF HER2-CAR T CELLS: Participant has a released cryopreserved HER2-CAR T cell product
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: Participant must have at least 1 brain lesion ( per RANO-Brain Metastases [BM] is not required-i.e., participant does not need to have at least 1 metastatic lesion >= 1 cm in longest dimension) that is new or increasing in size, or CSF cytology and/or radiographic findings consistent with leptomeningeal metastases
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: Participants whose brain metastases have been treated with whole brain radiation (WBRT) or stereotactic radiosurgery (SRS): previously radiated metastases must have >= 20% increase in longest diameter that is also >= 5 mm absolute increase from prior brain MRI or histopathologically proven recurrent tumor. Otherwise, new or not previously radiated lesions must be present

    • Note: Participants who have undergone local therapy (surgical resection or , or SRS), must have recovered from all acute side effects before starting treatment with HER2-CAR T cells
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: If a participant with brain metastases does not meet the above criteria, but there is still concern by the study team that changes in an enhancing brain lesion seen on brain MRI could be due to tumor progression, then the participant can undergo resection or biopsy of the lesion(s) to distinguish between tumor progression versus radiation necrosis. If there is histopathological evidence of tumor progression, then the participant can proceed with study treatment
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: Research participant does not have uncontrolled seizure following surgery prior to starting the first CAR T cell dose
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: Participants must have recovered from toxicity (=\< grade 1) of prior therapy (excluding alopecia and peripheral neuropathy)
  • ADDITIONAL ELIGIBILITY TO START CYCLE 1: Wash-out requirements (standard or investigational). The required waiting period between the last dose of the most recent chemotherapy agent(s) and first dose of HER2-CAR T cells is:

    • Four weeks for a cytotoxic chemotherapy, except for capecitabine, which will only require a 1 week waiting period from the last dose (on a dosing schedule of bid x 14 days, then off x 7 days);
    • At least 6 weeks must have passed since the completion of a nitrosourea-containing chemotherapy regimen;
    • At least four half-lives for a targeted agent

Exclusion criteria

Exclusion Criteria:

  • EXCLUSION CRITERIA FOR STUDY SCREENING: Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Research participants with a known history of congestive heart failure (CHF) or cardiac symptoms consistent with classification III-IV within 6 months prior to day 1 of protocol treatment, cardiomyopathy, myocarditis, myocardial infarction (MI), exposure to cardiotoxic medications or with clinical history suggestive of the above must have an and echocardiogram (ECHO) performed within 42 days prior to registration and as clinically indicated while on treatment.

    • Research participants with new symptoms of CHF, cardiomyopathy, myocarditis, MI, or exposure to cardiotoxic medications must have a cardiac consultation, creatinine phosphokinase (CPK), and troponin testing at pre study and as clinically indicated
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Research participant requires dialysis
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase 1 study. A legal guardian may substitute for the research participant
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant is unwilling to stop treatment with chemotherapy or endocrine therapy during the first 3 cycles of the -CAR T cell study
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant has a coagulopathy or bleeding disorder or cannot safely discontinue anticoagulation prior to placement of a Rickham reservoir
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant has a chronic or active viral infection of the CNS
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant has any uncontrolled illness, including ongoing or active infection; participant has known active or C infection; participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant is (HIV) seropositive based on testing performed within 4 weeks of screening
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant has an disease
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant has another active
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participants with lung (exception may be allowed per principal investigator [PI] discretion for participants that are not symptomatic from their lung metastases)
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant is unable to undergo a brain MRI
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Participant is breast feeding. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with HER2-CAR T cells, breastfeeding should be discontinued if the mother wants to participate in this study
  • EXCLUSION CRITERIA FOR STUDY SCREENING: Patient has a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment (HER2-CAR T cells) - TCM Central Memory T cell

    Patients receive HER2-CAR T cells (TCM Central Memory T cell) via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.

    Biological: Chimeric Antigen Receptor T-Cell Therapy

  • Experimental
    Treatment (HER2-CAR T cells) - TN/MEM Naive and Memory T cell

    Patients receive HER2-CAR T cells (TN/MEM Naive and Memory T cell) via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.

    Biological: Chimeric Antigen Receptor T-Cell Therapy

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    Rate and associated 90% Clopper and Pearson binomial confidence limits (90% CI) will be estimated for participants' experiencing DLTs at the recommended phase 2 dose schedule.

    Time frame: 21 days post T cell infusion

  2. Number of participants with treatment related adverse events

    Will be as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. Tables will be created to summarize all toxicities and side effects by dose, time post treatment, organ, severity and arm.

    Time frame: Up to 15 years

Secondary outcomes

  1. HER2-CAR T cells cerebrospinal fluid (CSF) and peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  2. Endogenous B cells in CSF and peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  3. T cells in CSF and peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  4. Myeloid cells in CSF and peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  5. Host immune subsets (e.g. T cell inhibitory/exhaustion markers, activation markers, and effector memory T cells) in CSF and peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  6. Cytokine levels in CSF

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  7. Cytokine levels in peripheral blood

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  8. Circulating tumor cells in the CSF

    Statistical and graphical methods will be used to describe the data.

    Time frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  9. Disease response in central nervous system (CNS)

    Will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria. Rates and 90% Clopper and Pearson Binomial Confidence limits will be calculated.

    Time frame: Progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  10. Systemic disease response

    Will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Rates and 90% Clopper and Pearson Binomial Confidence limits will be calculated.

    Time frame: Progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  11. Median CNS progression-free survival

    Kaplan Meier methods will be used.

    Time frame: Progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

  12. Median overall survival

    Kaplan Meier methods will be used.

    Time frame: From time of surgery up to 15 years

  13. HER2-CAR T cells detected in the tumor micro-environment

    Statistical and graphical methods will be used to describe the data.

    Time frame: From time of surgery up to 15 years

  14. Immune cell subsets in the tumor micro-environment

    Statistical and graphical methods will be used to describe the data.

    Time frame: From time of surgery up to 15 years

  15. Cytokine levels in the tumor micro-environment

    Statistical and graphical methods will be used to describe the data.

    Time frame: From time of surgery up to 15 years

  16. HER2 antigen expression levels

    Statistical and graphical methods will be used to describe the data.

    Time frame: From time of surgery up to 15 years

  17. Biomathematical modeling of tumor growth: perfusion and growth parameters based on serial brain magnetic resonance imaging

    Time frame: Progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)

08

Study locations

1 site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Jan 2027, 97 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 97 months is above that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2018
First posted
Oct 4, 2018
StartActual
Nov 27, 2018
Primary completionEst.
Jan 24, 2027
CompletionEst.
Jan 24, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03696030
Collaborators
National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Oct 4, 2018
Start date
Nov 27, 2018
Primary completion
Jan 24, 2027 (estimated)
Completion
Jan 24, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Jana L Portnow
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion